2020-05-11 16:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1-March 31, 2020
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so called...
2020-04-03 14:05
Infant Bacterial Therapeutics publishes Annual Report for 2019
Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2019. The report is available on IBT’s website ibtherapeutics.com...
2020-04-03 14:00
Infant Bacterial Therapeutics AB postpones Annual General Meeting
Due to the difficulty of gathering in larger groups, caused by the Corona Epidemic, IBT's Board of Directors has decided to postpone the Annual General...
2020-02-11 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2019
Message from the CEO IBT’s ongoing clinical phase III study with IBP-9414 has, as of the date of this year-end report, conducted patient recruitment...
2019-11-11 17:00
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2020
The Annual General Meeting of 2019 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene...
2019-11-07 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
Message from the CEO In our previous quarterly report we were able to announce that the first patient had been recruited in our clinical phase III-study...
2019-11-05 17:00
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with immediate effect due to the risk of conflict of interest that...
2019-08-21 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019 Message from the CEO On July 4 we were able to announce...
2019-07-04 14:15
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
IBT has recruited the first patient in the Phase III pivotal clinical study, The Connection Study. The development program for IBP-9414, of which The Connection...
IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed...